What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine

DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrot...

Full description

Bibliographic Details
Published in:Pharmaceutics
Main Authors: Urska Kamensek, Maja Cemazar, Simona Kranjc Brezar, Tanja Jesenko, Spela Kos, Katarina Znidar, Bostjan Markelc, Ziva Modic, Tilen Komel, Tim Gorse, Eva Rebersek, Helena Jakopic, Gregor Sersa
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Subjects:
Online Access:https://www.mdpi.com/1999-4923/15/7/1981
_version_ 1850405525761556480
author Urska Kamensek
Maja Cemazar
Simona Kranjc Brezar
Tanja Jesenko
Spela Kos
Katarina Znidar
Bostjan Markelc
Ziva Modic
Tilen Komel
Tim Gorse
Eva Rebersek
Helena Jakopic
Gregor Sersa
author_facet Urska Kamensek
Maja Cemazar
Simona Kranjc Brezar
Tanja Jesenko
Spela Kos
Katarina Znidar
Bostjan Markelc
Ziva Modic
Tilen Komel
Tim Gorse
Eva Rebersek
Helena Jakopic
Gregor Sersa
author_sort Urska Kamensek
collection DOAJ
container_title Pharmaceutics
description DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrotransfer (GET)-mediated delivery of plasmid DNA into skin and muscle tissues on a model of COVID-19 vaccine. Plasmids encoding the SARS-CoV-2 proteins spike (S) and nucleocapsid (N) were used as the antigen source, and a plasmid encoding interleukin 12 (IL-12) was used as an adjuvant. Vaccination was performed in the skin or muscle tissue of C57BL/6J mice on days 0 and 14 (boost). Two weeks after the boost, blood, spleen, and transfected tissues were collected to determine the expression of S, N, IL-12, serum interferon-γ, the induction of antigen-specific IgG antibodies, and cytotoxic T-cells. In accordance with prior in vitro experiments that indicated problems with proper expression of the S protein, vaccination with S did not induce S-specific antibodies, whereas significant induction of N-specific antibodies was detected after vaccination with N. Intramuscular vaccination outperformed skin vaccination and resulted in significant induction of humoral and cell-mediated immunity. Moreover, both boost and adjuvant were found to be redundant for the induction of an immune response. Overall, the study confirmed the feasibility of the GET for DNA vaccination and provided valuable insights into this approach.
format Article
id doaj-art-e1458df429704fbe9b25838babe718fb
institution Directory of Open Access Journals
issn 1999-4923
language English
publishDate 2023-07-01
publisher MDPI AG
record_format Article
spelling doaj-art-e1458df429704fbe9b25838babe718fb2025-08-19T22:48:34ZengMDPI AGPharmaceutics1999-49232023-07-01157198110.3390/pharmaceutics15071981What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 VaccineUrska Kamensek0Maja Cemazar1Simona Kranjc Brezar2Tanja Jesenko3Spela Kos4Katarina Znidar5Bostjan Markelc6Ziva Modic7Tilen Komel8Tim Gorse9Eva Rebersek10Helena Jakopic11Gregor Sersa12Institute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaBiotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, SloveniaBiotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, SloveniaBiotechnical Faculty, University of Ljubljana, Jamnikarjeva Ulica 101, SI-1000 Ljubljana, SloveniaInstitute of Oncology Ljubljana, Zaloska Cesta 2, SI-1000 Ljubljana, SloveniaDNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrotransfer (GET)-mediated delivery of plasmid DNA into skin and muscle tissues on a model of COVID-19 vaccine. Plasmids encoding the SARS-CoV-2 proteins spike (S) and nucleocapsid (N) were used as the antigen source, and a plasmid encoding interleukin 12 (IL-12) was used as an adjuvant. Vaccination was performed in the skin or muscle tissue of C57BL/6J mice on days 0 and 14 (boost). Two weeks after the boost, blood, spleen, and transfected tissues were collected to determine the expression of S, N, IL-12, serum interferon-γ, the induction of antigen-specific IgG antibodies, and cytotoxic T-cells. In accordance with prior in vitro experiments that indicated problems with proper expression of the S protein, vaccination with S did not induce S-specific antibodies, whereas significant induction of N-specific antibodies was detected after vaccination with N. Intramuscular vaccination outperformed skin vaccination and resulted in significant induction of humoral and cell-mediated immunity. Moreover, both boost and adjuvant were found to be redundant for the induction of an immune response. Overall, the study confirmed the feasibility of the GET for DNA vaccination and provided valuable insights into this approach.https://www.mdpi.com/1999-4923/15/7/1981DNA vaccinationgene electrotransferCOVID-19 vaccineimmunological adjuvantinterleukin 12
spellingShingle Urska Kamensek
Maja Cemazar
Simona Kranjc Brezar
Tanja Jesenko
Spela Kos
Katarina Znidar
Bostjan Markelc
Ziva Modic
Tilen Komel
Tim Gorse
Eva Rebersek
Helena Jakopic
Gregor Sersa
What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine
DNA vaccination
gene electrotransfer
COVID-19 vaccine
immunological adjuvant
interleukin 12
title What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine
title_full What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine
title_fullStr What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine
title_full_unstemmed What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine
title_short What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine
title_sort what we learned about the feasibility of gene electrotransfer for vaccination on a model of covid 19 vaccine
topic DNA vaccination
gene electrotransfer
COVID-19 vaccine
immunological adjuvant
interleukin 12
url https://www.mdpi.com/1999-4923/15/7/1981
work_keys_str_mv AT urskakamensek whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT majacemazar whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT simonakranjcbrezar whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT tanjajesenko whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT spelakos whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT katarinaznidar whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT bostjanmarkelc whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT zivamodic whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT tilenkomel whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT timgorse whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT evarebersek whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT helenajakopic whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine
AT gregorsersa whatwelearnedaboutthefeasibilityofgeneelectrotransferforvaccinationonamodelofcovid19vaccine